Case Study

Meridian Builds Robust Gene Therapy Research Program

Leveraging Advarra’s Integrated IRB and IBC Services

Meridian Clinical Research established a program for conducting clinical trials with cutting edge, genetically engineered vaccines.

Eight sites partnered with Advarra’s central institutional review board (IRB) and institutional biosafety committee (IBC) to ensure trial participant and staff safety when conducting gene therapy research.

The results:
  • An average four-day turnaround time for IBC approvals
  • Meridian sites were among the very first to be approved for a large Phase III COVID-19 vaccine study under Operation Warp Speed

Download the case study to learn more. 

Who should watch?

text goes here

CEU Credits

text goes here

Certificate of Attendance

text goes here

Time: 1 p.m. ET, 12 p.m. CT, 10 a.m. PT
Duration: 1 hour

Access Now